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INTRODUCTION 
 
 For several years proteomics research has been expected to lead to the finding of new 
markers that will translate into clinical tests applicable to samples such as serum, plasma and 
urine: so-called in vitro diagnostics (IVDs). Attempts to implement technologies applied in 
proteomics as 2DE, Immuno Blotting, Mass Spectrometry have initiated constructive 
discussions on opportunities and challenges inherent in such a translation process also with 
respect to the use of multi-marker profiling approaches and pattern signatures in IVD. It is 
mandatory to fulfil requirements in routine IVD, including disease prevention, diagnosis, 
prognosis, and treatment monitoring or follow up among others. To fulfill IVD requirements, 
it is essential to provide diagnostic tests that allow for definite and reliable diagnosis tied to a 
decision on interventions (prevention, treatment, or non treatment), meet stringent 
performance characteristics for each analyte (in particular test accuracy, including both 
precision of the measurement and trueness of the measurement), and provide adequate 
diagnostic accuracy, i.e., diagnostic sensitivity and diagnostic specificity, determined by the 
desired positive and negative predictive values which depend on disease frequency. The 
fulfilment of essential IVD requirements is mandatory in the regulated environment of modern 
diagnostics. Addressing IVD needs at an early stage can support a timely and effective 
transition of findings and developments into routine diagnosis. IVD needs reflect features that 
are useful in clinical practice. This helps to generate acceptance and assists the implementation 
process1. 
 The medical need for relevant biomarkers is enormous. This is particularly true for the 
many types of cancer, but other diseases such as Type 1 diabetes (DMT1) also lack useful and 
adequate diagnostic markers with high specificity and sensitivity. Despite advances in imaging 
technologies for early detection of diseases, proteomic and peptidomic multiplex techniques 
and metabolomics statistical analysis have evolved in recent years2. 
 
Diagnosis/Screening of Bladder Cancer 
  
 The bladder is an organ located in the pelvic cavity that stores and discharges urine. 
Urine is produced by the kidneys, carried to the bladder by the ureters, and discharged from 
the bladder through the urethra3. Bladder cancer accounts for approximately 90% of cancers of 
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the urinary tract (renal pelvis, ureters, bladder, urethra). Bladder cancer usually originates in 
the bladder lining, which consists of a mucous layer of surface cells that expand and deflate 
(transitional epithelial cells), smooth muscle, and a fibrous layer. Tumors are categorized as 
low-stage (superficial) or high-stage (muscle invasive). In industrialized countries (e.g., 
United States, Canada, France), more than 90% of cases originate in the transitional epithelial 
cells (called transitional cell carcinoma; TCC). In developing countries, 75% of cases are 
squamous cell carcinomas caused by Schistosoma haematobium (parasitic organism) 
infection. Rare types of bladder cancer include small cell carcinoma, carcinosarcoma, primary 
lymphoma, and sarcoma.According to the National Cancer Institute, the highest incidence of 
bladder cancer occurs in industrialized countries such as the United States, Canada, and 
France. Bladder cancer is the fourth most common type of cancer in men and the eighth most 
common type in women. The disease is more prevalent in Caucasians than in African 
Americans and Hispanics.  
 
Causes and Risk Factors  
 Cancer-causing agents (carcinogens) in the urine may lead to the development of 
bladder cancer. Cigarette smoking contributes to more than 50% of cases, and smoking cigars 
or pipes also increases the risk. Other risk factors include the following:  
 
• Age  
• Chronic bladder inflammation (recurrent urinary tract infections, urinary stones)  
• Consumption of Aristolochia fangchi (herb used in some weight-loss formulas)  
• Diet high in saturated fat  
• Exposure to second-hand smoke  
• External beam radiation  
• Family history of bladder cancer (several genetic risk factors identified)  
• Gender (male)  
• Infection with Schistosoma haematobium (parasite found in many developing countries)  
• Personal history of bladder cancer  
• Race (Caucasian)  
• Treatment with certain drugs (e.g., cyclophosfamide - used to treat cancer)  
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 Exposure to carcinogens in the workplace also increases the risk for bladder cancer. 
Medical workers exposed during the preparation, storage, administration, or disposal of 
antineoplastic drugs (used in chemotherapy) are at increased risk. The primary symptom of 
bladder cancer is blood in the urine (hematuria). Hematuria may be visible to the naked eye 
(gross) or visible only under a microscope (microscopic) and is usually painless. Other 
symptoms include frequent urination and pain upon urination (dysuria)4.  
 Diagnosis of bladder cancer includes urological tests and imaging tests. A complete 
medical history is used to identify potential risk factors (e.g., smoking, exposure to dyes).  
Laboratory tests may include the following:  
• NMP22®BladderChek® (to detect elevated levels of tumor markers in the urine)  
• Urinalysis (to detect microscopic hematuria)  
• Urine cytology (to detect cancer cells by examining cells flushed from the bladder during 
urination)  
• Urine culture (to rule out urinary tract infection)  
• NMP22®BladderChek® is a urine test used to detect elevated levels of a nuclear matrix 
protein (called NMP22®). Bladder cancer increases levels of this protein in the urine, 
even during early stages of the disease.  
• Results of this test, which is non invasive and is performed in a physician’s office, are 
available during the patient's office visit. Studies have shown that when used with 
cystoscopy, NMP22®BladderChek® may be more effective than other diagnostic tests 
(e.g., urine tests or cystoscopy alone).  
 Various imaging tests may also be performed. Intravenous pyelogram (IVP) is the 
standard imaging test for bladder cancer. In this procedure, a contrast agent (radiopaque dye) 
is administered through a vein (intravenously) and x-rays are taken as the dye moves through 
the urinary tract. IVP provides information about the structure and function of the kidneys, 
ureters, and bladder. Other imaging tests include CT scan, MRI scan, bone scan, and 
ultrasound. If bladder cancer is suspected, cystoscopy and biopsy are performed. Local 
anesthesia is administered and a cystoscope (thin, telescope-like tube with a tiny camera 
attached) is inserted into the bladder through the urethra to allow the physician to detect 
abnormalities. In biopsy, tissue samples are taken from the lesion(s) and examined for cancer 
cells. If the sample is positive, the cancer is staged using the tumor, node, metastases (TNM) 
system3.  
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Biomarker discovery 
Biomarkers are important tools that can supply some of the needed information, 
especially when used in conjunction with traditional clinical and laboratory data. A biomarker 
is a biologic characteristic that is measured and evaluated objectively as an indicator of normal 
biologic processes, pathogenic processes, or pharmacologic response to therapeutic 
intervention. Biomarkers may be any parameter of a patient that can be measured, for 
example, mRNA expression profiles, proteins metabolites, peptides, proteomic patterns, lipids, 
imaging methods, or electrical signals. The best biomarkers are accurate, relatively 
noninvasive and easy-to-perform tests that can be done at the bedside or in the outpatient 
setting. These tests involve a blood or spot urine specimen, can be measured serially, and have 
a fast turnaround5.  
Recently, functional studies have emphasized analyses at the level of gene expression 
(transcriptomics), protein expression (proteomics) and now the metabolic network 
(metabolomics) with a view of the “systems biology” approach of defining the phenotype and 
bridging the phenotype- to - genotype divide. Metabolomics is the one of the latest in the 
string of “omic” technologies, involving the comprehensive analysis in which all the 
metabolites of an organism are identified and quantified6. The biochemical response of an 
organism to a perturbation can be characterised by its effect on the differential accumulation 
of individual metabolites7. Metabolomics aims at the comprehensive and quantitative analysis 
of wide arrays of metabolites in biological samples. These numerous analytes have very 
diverse physico-chemical properties and occur at different abundance levels. Consequently, 
comprehensive metabolomics investigations are primarily a challenge for analytical chemistry 
and specifically mass spectrometry has vast potential as a tool for this type of investigation. 
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Mass spectrometry 
 
Mass spectrometry is an analytical tool used for measuring the molecular mass of a 
sample. For large samples such as biomolecules, molecular masses can be measured to within 
an accuracy of 0.01% of the total molecular mass of the sample i.e. within a 4 Daltons (Da) or 
atomic mass units (amu) error for a sample of 40,000 Da. This is sufficient to allow minor 
mass changes to be detected, e.g. the substitution of one amino acid for another, or a post-
translational modification. For small organic molecules the molecular mass can be measured 
to within an accuracy of 3 ppm or less, which is often sufficient to confirm the molecular 
formula of a compound, and is also a standard8. 
Structural information can be generated using certain types of mass spectrometers, 
usually those with multiple analyzers which are known as tandem mass spectrometers. This is 
achieved by fragmenting the sample inside the instrument and analysing the products 
generated. This procedure is useful for the structural elucidation of organic compounds and for 
peptide or oligonucleotide sequencing.  
Mass spectrometers are used in industry and academia for both routine and research 
purposes. The following list is just a brief summary of the major mass spectrometric 
applications:  
Biotechnology: the analysis of proteins, peptides, oligonucleotides  
Pharmaceutical: drug discovery, combinatorial chemistry, pharmacokinetics, drug 
metabolism  
Clinical: neonatal screening, haemoglobin analysis, drug testing  
Environmental: PAHs, PCBs, water quality, food contamination  
Geological: oil composition  
Especially mass spectrometry help biochemists in accurate:  
Accurate molecular weight measurements: sample confirmation, to determine the purity of a 
sample, to verify amino acid substitutions, to detect post-translational modifications, to 
calculate the number of disulphide bridges  
Reaction monitoring: to monitor enzyme reactions, chemical modification, protein digestion  
Amino acid sequencing: sequence confirmation, de novo characterisation of peptides, 
identification of proteins by database searching with a sequence "tag" from a proteolytic 
fragment  
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Oligonucleotide sequencing: the characterisation or quality control of oligonucleotides  
Protein structure: protein folding monitored by H/D exchange, protein-ligand complex 
formation under physiological conditions, macromolecular structure determination 
 
Instrumentation 
 
Mass spectrometers can be divided into five fundamental parts, namely the inlet 
system, the ionization source , the analyzer, the detector and the data system. The sample has 
to be introduced into the ionization source of the instrument. Once inside the ionization 
source, the sample molecules are ionized, because ions are easier to manipulate than neutral 
molecules. These ions are extracted into the analyzer region of the mass spectrometer where 
they are separated according to their mass (m) -to-charge (z) ratios (m/z) . The separated ions 
are detected and this signal sent to a data system where the m/z ratios are stored together with 
their relative abundance for presentation in the format of a m/z spectrum. The analyzer and 
detector of the mass spectrometer, and often the ionization source too, are maintained under 
high vacuum to give the ions a reasonable chance of travelling from one end of the instrument 
to the other without any hindrance from air molecules. The entire operation of the mass 
spectrometer, and often the sample introduction process also, is under complete data system 
control on modern mass spectrometers8 (Fig 1)  
 
 
 
 
 
 
(Fig 1) Mass spectrometer logical shìcheme 
 
Sample introduction  
The method of sample introduction to the ionizations source often depends on the 
ionizations method being used, as well as the type and complexity of the sample. The sample 
can be inserted directly into the ionization source like Target Plate in Matrix Assisted Laser 
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ionization source. This latter method of sample introduction usually involves the mass 
spectrometer being coupled directly to a high performance liquid chromatography (HPLC), 
gas chromatography (GC) or capillary electrophoresis (CE) separation column, and hence the 
sample is separated into a series of components which then enter the mass spectrometer 
sequentially for individual analysis8 
 
Ionization methods 
 A fundamental challenge to the application of mass spectrometry to any class of 
analytes is the production of gas-phase ions of those species, and difficulties in producing gas-
phase ions can prevent mass spectrometric analysis of certain class of molecules. Many 
ionization methods are available and each has its own advantages and disadvantages9. The 
ionization methods used for the majority of biochemical analyses are Electro Spray Ionization 
(ESI) and Matrix Assisted Laser Desorption Ionization (MALDI) , and these are described in 
more detail in Sections 5 and 6 respectively. With most ionization methods there is the 
possibility of creating both positively and negatively charged sample ions, depending on the 
proton affinity of the sample8.  
 
Electrospray ionization 
Electrospray Ionisation (ESI) (Fig.2) is one of the Atmospheric Pressure Ionisation 
(API) techniques and is well-suited to the analysis of polar molecules ranging from less than 
100 Da to more than 1,000,000 Da in molecular mass; ESI is known as a "soft" ionization 
method as the sample is ionised by the addition or removal of a proton. During standard 
electrospray ionisation10, the sample is dissolved in a polar, volatile solvent and pumped 
through a narrow, stainless steel capillary (75 - 150 micrometers i.d.) at a flow rate of between 
1 µL/min and 1 mL/min. A high voltage of 3 or 4 kV is applied to the tip of the capillary, 
which is situated within the ionization source of the mass spectrometer, and as a consequence 
of this strong electric field, the sample emerging from the tip is dispersed into an aerosol of 
highly charged droplets, a process that is aided by a co-axially introduced nebulizing gas 
flowing around the outside of the capillary. This gas, usually nitrogen, helps to direct the spray 
emerging from the capillary tip towards the mass spectrometer. The charged droplets diminish 
in size by solvent evaporation, assisted by a warm flow of nitrogen known as the drying gas 
which passes across the front of the ionization source. Eventually charged sample ions, free 
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from solvent, are released from the droplets, some of which pass through a sampling cone or 
orifice into an intermediate vacuum region, and from there through a small aperture into the 
analyzer of the mass spectrometer, which is held under high vacuum. To enhanced sensitivity 
more instrument were equipped with a low flow rate version of electrospray ionizations, called 
nanoESI11. 
In positive ionization mode, a trace of formic acid is often added to aid protonation of 
the sample molecules; in negative ionization mode a trace of ammonia solution or a volatile 
amine is added to aid deprotonation of the sample molecules. Proteins and peptides are usually 
analyzed under positive ionization conditions and saccharides and oligonucleotides under 
negative ionization conditions. In all cases, the m/z scale must be calibrated by analyzing a 
standard sample of a similar type to the sample being analyzed (e.g. a protein calibrant for a 
protein sample), and then applying a mass correction8. 
 
 
 
 
 
 
 
 
 
 
                                        (Fig 2) ESI source 
 
In ESI, samples (M) with molecular masses up to ca. 1200 Da give rise to singly 
charged molecular-related ions, usually protonated molecular ions of the formula (M+H)+ in 
positive ionization mode, and deprotonated molecular ions of the formula (M-H)- in negative 
ionization mode. Samples (M) with molecular weights greater than ca. 1200 Da give rise to 
multiply charged molecular-related ions such as (M+nH)n+ in positive ionization mode and 
(M-nH)n- in negative ionization mode. Proteins have many suitable sites for protonation as all 
of the backbone amide nitrogen atoms could be protonated theoretically, as well as certain 
amino acid side chains such as lysine and arginine which contain primary amine 
 11
functionalities. If the number of charges on an ion is known, then it is simply a matter of 
reading the m/z value from the spectrum and solving the above equation to determine the 
molecular weight of the sample. Usually the number of charges is not known, but can be 
calculated if the assumption is made that any two adjacent members in the series of multiply 
charged ions differ by one charge. This may seem long-winded but fortunately the molecular 
mass of the sample can be calculated automatically, or at least semi-automatically, by the 
processing software associated with the mass spectrometer called deconvolution8.  
 
MALDI   
Matrix assisted laser desorption ionization12 deals well with thermolabile, non-volatile 
organic compounds especially those of high molecular mass and is used successfully in 
biochemical areas for the analysis of proteins, peptides, glycoproteins, oligosaccharides, and 
oligonucleotides. It is relatively straightforward to use and reasonably tolerant to buffers and 
other additives. The mass accuracy depends on the type and performance of the analyser of the 
mass spectrometer, but most modern instruments should be capable The sample to be analysed 
is dissolved in an appropriate volatile solvent, usually with a trace of trifluoroacetic acid if 
positive ionisation is being used, at a concentration of ca. 10 pmol/µL and an aliquot (1-2 µL) 
of this removed and mixed with an equal volume of a solution containing a vast excess of a 
matrix. A range of compounds is suitable for use as matrices: sinapinic acid is a common one 
for protein analysis while alpha-cyano-4-hydroxycinnamic acid is often used for peptide 
analysis. An aliquot (1-2 µL) of the final solution is applied to the sample target which is 
allowed to dry prior to insertion into the high vacuum of the mass spectrometer. The laser 
(Fig.3) is fired, the energy arriving at the sample/matrix surface optimised, and data 
accumulated until a m/z spectrum of reasonable intensity has been amassed. The time-of-flight 
analyser separates ions according to their mass(m)-to-charge(z) (m/z) ratios by measuring the 
time it takes for ions to travel through a field free region known as the flight, or drift, tube. 
The heavier ions are slower than the lighter ones. The m/z scale of the mass spectrometer is 
calibrated with a known sample that can either be analysed independently (external 
calibration) or pre-mixed with the sample and matrix (internal calibration). of measuring 
masses to within 0.01% of the molecular mass of the sample, at least up to ca. 40,000 Da. 
MALDI is based on the bombardment of sample molecules with a laser light to bring about 
sample ionization. The sample is pre-mixed with a highly absorbing matrix compound for the 
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most consistent and reliable results, and a low concentration of sample to matrix works best. 
The matrix transforms the laser energy into excitation energy for the sample, which leads to 
sputtering of analyte and matrix ions from the surface of the mixture. In this way energy 
transfer is efficient and also the analyte molecules are spared excessive direct energy that may 
otherwise cause decomposition. Most commercially available MALDI mass spectrometers 
now have a pulsed nitrogen laser of wavelength 337 nm. MALDI is also a "soft" ionisation 
method and so results predominantly in the generation of singly charged molecular-related 
ions regardless of the molecular mass, hence the spectra are relatively easy to interpret. 
Fragmentation of the sample ions does not usually occur8.  
 
 
 
 
 
 
 
 
 
 
                                                   (Fig 3) MALDI Source 
 
Analyzers 
The analyzer uses dispersion or filtering to sort ions according to their mass-to-charge 
ratios or a related property. The most widely used analyzers are magnetic sectors, quadrupole 
mass filters, quadrupole ion traps, Fourier transform ion cyclotron resonance spectrometers, 
and time-of-flight mass analyzers.  
The first type of mass analyzer to consider is quadrupole mass filter, consists of four 
parallel poles or rods. In this device (Fig.4), mass sorting depends on ion motion resulting 
from simultaneously applied constant (dc) and radio frequency electric (rf) electric fields. 
Scanning is accomplished by systematically changing the field strengths, thereby changing the 
m/z value that is transmitted through the analyzer. Quadrupole mass spectrometers provide 
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lower resolution than double focusing instruments but tend to be more easily interfaced to 
various inlet systems and to be less costly. 
 
 
 
 
 
 
 
 
                                       (Fig 4) Quadrupole analyzer 
 
 
Time-of-flight mass analyzers (Figure.5), usually coupled with MALDI separate ions 
by virtue of their different flight times over a known distance. A brief burst of ions is emitted 
from a source. These ions are accelerated so that ions of like charge have equal kinetic energy 
and then are directed into a flight tube. Since kinetic energy is equal to 1/2 mv2, where m is 
the mass of the ion and v is the ion velocity, the lower the ion's mass, the greater the velocity 
and shorter its flight time. The travel time from the ion source through the flight tube to the 
detector, measured in microseconds, can be transformed to the m/z value through the 
relationships described above. Because all ion masses are measured for each ion burst, TOF 
mass spectrometers offer high sensitivity as well as rapid scanning. They can provide mass 
data for very high-mass biomolecules8. 
 
 
 
 
 
 
 
 
 
              (Fig 5) Time-of-flight mass analyzers 
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Improved mass resolution in MALDI TOF-MS has been obtained by the utilization of 
a single-stage or a dual-stage reflectron (RETOF-MS). The reflectron, located at the end of the 
flight tube, is used to compensate for the difference in flight times of the same m/z ions of 
slightly different kinetic energies by means of an ion reflector. This results in focusing the ion 
packets in space and time at the detector. Enhancing the mass resolution can also increase the 
mass accuracy when determining the ion's mass. Another contribution to mass resolution loss 
in conventional (i.e., continuous ion extraction) linear MALDI TOF-MS is attributed to a 
range of flight times of identical m/z ions due to different initial velocities. A fraction of the 
final velocity that is attained for particular m/z ions as they are accelerated out of the ion 
source and into the field free region includes this initial velocity component. No compensation 
is made with continuous ion extraction linear TOF-MS for ions with the same m/z but 
different initial ion velocities. Improvements in mass resolution can be achieved by utilizing 
delayed pulsed ion extraction1314 (DE) can compensate for the initial velocity distribution of 
the MALDI generated ion packet such that same m/z ions arrive simultaneously at a space 
focal plane located at the detector. Broadening of the ion velocity distribution due to 
collisional processes in the ion source can also be minimized by allowing the dense plume of 
MALDI generated ions/neutrals to dissipate prior to ion draw out from the ion source. This 
results in narrower ion arrival time distributions and provides better mass resolution when 
compared to continuous ion extraction. 
 
Tandem mass spectrometry (MS/MS) 
 
Tandem mass spectrometry (MS/MS) is used to produce structural information about a 
compound by fragmenting specific sample ions inside the mass spectrometer and identifying 
the resulting fragment ions. This information can then be pieced together to generate structural 
information regarding the intact molecule. Tandem mass spectrometry also enables specific 
compounds to be detected in complex mixtures on account of their specific and characteristic 
fragmentation patterns. A tandem mass spectrometer is a mass spectrometer that has more than 
one analyzer, in practice usually two. The two analyzers are separated by a collision cell into 
which an inert gas (e.g. argon, xenon) is admitted to collide with the selected sample ions and 
bring about their fragmentation (Fig.6). 
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The basic modes of data acquisition for tandem mass spectrometry experiments are as 
follows:  
Product or daughter ion scanning:  
the first analyser is used to select user-specified sample ions arising from a particular 
component; usually the molecular-related (i.e. (M+H)+ or (M-H)-) ions. These chosen ions 
pass into the collision cell, are bombarded by the gas molecules which cause fragment ions to 
be formed, and these fragment ions are analysed i.e. separated according to their mass to 
charge ratios, by the second analyser. All the fragment ions arise directly from the precursor 
ions specified in the experiment, and thus produce a fingerprint pattern specific to the 
compound under investigation. This type of experiment is particularly useful for providing 
structural information concerning small organic molecules and for generating peptide 
sequence information15.  
Precursor or parent ion scanning:  
the first analyser allows the transmission of all sample ions, whilst the second analyser 
is set to monitor specific fragment ions, which are generated by bombardment of the sample 
ions with the collision gas in the collision cell. This type of experiment is particularly useful 
for monitoring groups of compounds contained within a mixture which fragment to produce 
common fragment ions, e.g. glycosylated peptides in a tryptic digest mixture, aliphatic 
hydrocarbons in an oil sample, or glucuronide conjugates in urine15.  
 
Constant neutral loss scanning:  
this involves both analyzers scanning, or collecting data, across the whole m/z range, 
but the two are off-set so that the second analyser allows only those ions which differ by a 
certain number of mass units (equivalent to a neutral fragment) from the ions transmitted 
through the first analyser. e.g. This type of experiment could be used to monitor all of the 
carboxylic acids in a mixture. Carboxylic acids tend to fragment by losing a (neutral) molecule 
of carbon dioxide, CO2, which is equivalent to a loss of 44 Da or atomic mass units. All ions 
pass through the first analyser into the collision cell. The ions detected from the collision cell 
are those from which 44 Da have been lost15.  
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Selected/multiple reaction monitoring:  
both of the analyzers are static in this case as user-selected specific ions are transmitted 
through the first analyser and user-selected specific fragments arising from these ions are 
measured by the second analyser. The compound under scrutiny must be known and have 
been well-characterised previously before this type of experiment is undertaken. This 
methodology is used to confirm unambiguously the presence of a compound in a matrix e.g. 
drug testing with blood or urine samples. It is not only a highly specific method but also has 
very high sensitivity15.  
 
 
 
 
 
 
 
 
 
 
 
 
 
    (Fig 6) Tandem mass spectrometry 
 
 
Peptide Sequencing by Tandem Mass Spectrometry.  
The most common usage of MS/MS in biochemical areas is the product or daughter ion 
scanning experiment which is particularly successful for peptide and nucleotide sequencing. 
Peptides fragment in a reasonably well-documented manner1617.The protonated molecules 
fragment along the peptide backbone and also show some side-chain fragmentation with 
certain instruments18. There are three different types of bonds that can fragment along the 
amino acid backbone: the NH-CH, CH-CO, and CO-NH bonds. Each bond breakage gives rise 
to two species, one neutral and the other one charged, and only the charged species is 
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monitored by the mass spectrometer(Fig.7). The charge can stay on either of the two 
fragments depending on the chemistry and relative proton affinity of the two species. Hence 
there are six possible fragment ions for each amino acid residue and these are labelled as in the 
diagram, with the a, b, and c" ions having the charge retained on the N-terminal fragment, and 
the x, y", and z ions having the charge retained on the C-terminal fragment. The most common 
cleavage sites are at the CO-NH bonds which give rise to the b and/or the y" ions. The mass 
difference between two adjacent b ions, or y"; ions, is indicative of a particular amino acid 
residue (see Table of amino acid residues at the end of this document). The extent of side-
chain fragmentation detected depends on the type of analysers used in the mass spectrometer. 
A magnetic sector - magnetic sector instrument will give rise to high energy collisions 
resulting in many different types of side-chain cleavages. Triple quadrupole and quadrupole-
time-of-flight mass spectrometers generate low energy fragmentations with fewer types of 
side-chain fragmentations.  
 
 
 
 
 
 
 
 
 
 
                                     (Fig 7) Peptide fragmentation 
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Statistical methods  
 
Over the last decade or so a new body of practice has become standard in 
computational analysis. It is known variously as corpus-based, empirical, or statistical 
methods of data analysis, most common being the simple rubric statistical methods. Present-
day computational analysis differs from “traditional” computational methods in the 
pervasiveness of probabilities in its theoretical models, the centrality of large data collections, 
including multidisciplinary data and integrated databases, and the emphasis on rigorous 
empirical evaluation. The change in computational analysis is part of a larger shift to statistical 
methods in computer science, particularly in artificial intelligence, pattern recognition, speech 
recognition, and machine learning. In this study were employed PCA and LDA like statistical 
approach to analyze our data. 
Principal component analysis (PCA) involves a mathematical procedure that 
transforms a number of (possibly) correlated variables into a (smaller) number of uncorrelated 
variables called principal components. The first principal component accounts for as much of 
the variability in the data as possible, and each succeeding component accounts for as much of 
the remaining variability as possible PCA is a linear transformation that transforms the data to 
a new coordinate system such that the greatest variance by any projection of the data comes to 
lie on the first coordinate (called the first principal component), the second greatest variance 
on the second coordinate, and so on. PCA can be used for dimensionality reduction in a 
dataset while retaining those characteristics of the dataset that contribute most to its variance, 
by keeping lower-order principal components and ignoring higher-order ones. Such low-order 
components often contain the "most important" aspects of the data. But this is not necessarily 
the case, depending on the application. This technique allows to discover or to reduce the 
dimensionality of the data set and to identify new meaningful underlying variables19.  
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AIMS 
 
 This study focuses on the development and application of metabolomics technologies 
to peptides in urine of Bladder Cancer. Numerous attempts made in the understanding of the 
molecular mechanisms of many pathologies, among which tumours; much still remains 
unknown with regards to pathogenesis, with the end results being the development of an 
efficient strategy for early diagnosis and early cure. The analysis of small molecule, peptide 
and metabolites expressions of tissues from patients affected with tumours and various 
diseases are surely an ideal starting point. With this aim, proteomics coupled statistical 
methods is therefore a good method for this study: 
? knowledge of metabolites variations rising from pathological states; 
? the development of new biological markers for early diagnosis detection of the disease; 
? identification of new therapeutic targets; 
? the evaluation of therapeutic and toxic effects of new drugs. 
 For the research of tumour markers, the most common approach used so far has been 
the comparison of healthy and unhealthy tissues in other to identify particular protein patterns 
that are characteristic of tumour cells with respect to healthy cells.  
 Peptidomics technologies provide new opportunities for the detection of low-
molecular-weight proteome biomarkers (peptides) by mass spectrometry. Improvements in 
peptidomics research are based on separation of peptides and/or proteins by their 
physicochemical properties in combination with mass spectrometric detection, identification 
and sophisticated bioinformatics tools for data analysis. 
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MATERIALS AND METHODS 
 
Sample Preparation 
 
In order to isolate selectively small organic molecules fraction of a complex substrate, 
like urine, was necessary to develop a purification method, to produce the highest content of 
metabolites and minor amounts of interference, we had testing a wide variety of protocols and 
techniques.  
The first step of each tested method had required to eliminate intact cells (endogen or 
hexogen) or epithelium piece, so spontaneous urine samples were collected, immediately 
frozen, and stored at -20 °C. After thawing, the urine samples (10ml) were centrifuged for 20 
min at 1000 rpm. 
The second step involves the removal of the protein fraction. The supernatant was 
slowly denaturated with a linear temperature ramp: 35 ° C to 95 ° C per 120 minutes in a gas-
chromatography oven to obtain most reproducibility (DT).:It is important that the 
denaturating temperature is reached slowly in order to favour the digestion of the colloidal 
precipitates and to avoid the inclusion of peptides inside the proteic clusters. Or as a method to 
remove protein fraction tested was chemical denaturation: we preformed these by three time 
volume of CH3CN in agitation for 30 min. Each sample was concentrated to 3 ml, 
centrifugated at 13000 rpm for 15 min and the supernatant was applied onto a Size Exclusion 
Chromatography (SEC) column packed “in-house” with Sephadex G10 (Sigma-Aldrich) to 
remove salts, urea, electrolytes, and other interfering matrix components. Alternatively we 
performed salt elimination by Solid Phase Extraction (SPE) in two kind of Reverse Phase 
preparative microcolumn: Strata C18 by Phenomenex and AmprepTM C2 by Amersham 
Bioscences20. Collected fractions were lyophilized and recovered with 500 µL HPLC-grade 
water, to enhance the amount of peptides injected  
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MS/MS analysis 
We have tested more instrument setup as so HPLC column, calibration and ionization 
technology; the goal is follow described  
Metabolite mixture in mQ water are the better substrate to LC-MS/MS analysis. 5 µL 
of this solution were analyzed using a nanoflow capillary liquid chromatography coupled with 
nanoelectrospray quadrupole time of flight tandem mass spectrometry (nanoESI Q-TOF 
MS/MS). The Q-Tof Ultima (Waters, UK) was equipped with CapLC with autosampler 
(Waters, UK) using a ten port zero dead volume valve (Valco-Vici) enabling fast sample 
loading on a precolumn (Opti-Pack, Symmetry 300 C18, 5 µm, Waters) with a isocratically 
flow rate of 20 µl/min for 5 min with solvent A delivered by auxiliary pump C to wash sample 
from residuals salt. After back-flushing washing of the pre-column, the ten-port valve was 
switched allowing delivery of a linear solvent B gradient 10-95% in 55 min21 (solvent A: H2O 
with 0.2% formic acid and 2% CH3CN; solvent B: CH3CN with 0.2% formic acid) with a flow 
rate of 200 nl/min after split onto the analytical column (NS-AC-12 BioSphere C18, 150 mm x 
75 µm, 5 µm, by NanoSeparation). NanoESI MS/MS tandem spectra were recorded in the 
automated MS to MS/MS switching mode, with a m/z-dependent set of collision energy offset 
values. Singly to quadruply charged ions were selected and fragmented, with argon in 
collision gas cell. External calibration was performed in MS/MS mode by a solution of Glu1-
Fibrinopeptide B (Sigma-Aldrich) 300 fM in H20/CH3CN 50/50 and 0.2% HCOOH; the same 
solution was employed to “Lock Mass Calibration” by PressurePump (WatersTM). NanoESI 
source was equipped by Universal Spray (Waters TM) to increase stability of spray through 
PicoTip TM Emitter (metallized silica tip i.d. 10 to 5 µm by New Objective) 
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MALDI-MS analysis 
We have trialed if was possible acquire the same information by MALDI-TOF analysis 
since this technologies is faster and cheaper than LC-MS/MS. 1 µL of purified sample was 
added to 1 µL of MALDI matrix solution (a-Cyano-4-Hydroxycinnamic Acid, 10 µg/µl in 
H2O/CH3CN/TFA:60/40/0.1) and spotted onto target plate. Spectra were acquired by MALDI 
Micro MX (Waters, UK) in positive ionization and reflectron mode. Eternal calibration was 
performed with PEG-NaI (Waters mix calib. Solution) from 600 Da to 5000 Da; we used the 
same range to acquired sample spectra. 
  
Spectra Interpretation  
Mass data collected during an RP-LC-MS/MS analysis were processed by Protein 
Lynx Global Server (Waters, UK) and converted into a PKL file to be submitted:  
• statistical elaboration with PCA approach, 
• mathematical elaboration to feature selection: to identify “target” signal 
• automated database searching “Mascot , MS/MS Ions Search” (available in house).  
Data base search parameters were: parent tolerance 0.2 Da, fragment tolerance 0.1 Da, 
database SWISSPROT22. PCA was performed by SimcaP+ (Umetrics) to obtain variable space 
reduction in a plots of the first three components that allowed visualisation of the data and to 
establish whether there were any intrinsic healthy/unhealthy-related differences in the 
metabolic composition of the urine. 
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RESULTS & CONCLUSION 
 
 MALDI spectra showed in fig.8. is representative of all tested purification method. The 
number of signals is unsatisfactory, probably because presence salt residual decrease 
ionization whereas in LC-MS/MS analysis are removed during washing on precolumn 
 
 
 
 
 
 
 
                                (Fig 8.) MALDI-TOF spectra 
 
LC-MS/MS chromatograms showed below (Figg.9-14) display the trend signal according to 
the methods of purification tested 
 
 
 
 
 
 
 
 
 
                            (Fig 9) MS/MS chromatogram generate after chemical denaturation and SPE C18 
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                           (Fig 10.) MS/MS chromatogram generate after chemical denaturation and SPE C2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                           (Fig 11) MS/MS chromatogram generate after chemical denaturation and SEC 
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                          (Fig 12) MS/MS chromatogram generate after thermal denaturation and SPE C18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                           (Fig 13.) MS/MS chromatogram generate after  thermal denaturation and SPE C2 
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                         (Fig 14) MS/MS chromatogram generate after  thermal denaturation and SEC 
 
In each chromatogram can be seen the first channel due to the current generated by 
intact peptide onto detector, in the upper acquisition channels can see the signals generated by 
the amino acid chains fragmentation. Amount of signals presented by various chromatograms 
allow to say that the thermal denaturation followed by SEC is the most sensitive method. 
Mascott submission of PKL file generate by process of these chromatogram return 
“Uromoduline Precuror”; not significative hit because uromoduline is most aboundante 
protein in urine (Fig15). 
 27
 
 
 
Database:  SwissProt 46.2 (221901 sequences; 100660862 residues) 
Taxonomy:  Homo sapiens (human) (48408 sequences) 
Significant hits:  
P07911-00-00-00  (UROM_HUMAN) Splice isoform Displayed; Variant Displayed; Conflict 
Displayed; from P07911 Uromodulin precursor (Tamm-Horsfall urinary glycoprotein) (THP) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obser. Mr(expt) Mr(calc) Delta Score Expect Rank Peptide
491.83   981.64   981.60  0.04 40  1.7  1   VLNLGPITR
561.01   1680.01  1679.97  0.04 111  1.2e-07 1   VIDQSRVLNLGPITR
884.54   1767.07  1767.00  0.07 81  0.00012 1   SVIDQSRVLNLGPITR
956.55   1911.08  1911.05  0.03 134  6.4e-10 1   SGSVIDQSRVLNLGPITR
680.74   2039.21  2039.15  0.06 57  0.035  1   SGSVIDQSRVLNLGPITRK
 
(Fig. 15) Uromodulin identification by match MS/MS spectra in Mascott 
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 Mathematic elaboration of the molecular masses of the series of peptides obtained by 
pathologic and control urine to feature selection has given some particular or important 
abundant targets that are present in tumours and are relatively or scarsely present or absent in 
controls. The cluster formed by these series (Tab 1 A-B) of peptides might provide an early, 
rapid and non invasive diagnosis system at a relatively low cost.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          Tab. 1 B 
 
 
 
 
 
 
 
 
Tab. 1 A 
M.W.  
Peptide 
Frequency 
Bladder Cancer 
Frequency 
Control 
1735.8 56.25 6.25 
2190.8 56.25 50 
2800.1 50 75 
4949.9 50 25 
2843.1 50 18.75 
1022.4 43.75 25 
6186.3 43.75 18.75 
2305.9 37.5 18.75 
2844.2 37.5 18.75 
4984.1 37.5 0 
1898.9 31.25 43.75 
731.3 31.25 6.25 
4844.0 31.25 0 
2345.0 31.25 0 
1489.0 25 6.25 
1942.7 25 0 
2017.1 25 0 
2307.3 18.75 0 
M.W.  
Peptide 
Frequency 
Bladder Cancer 
Frequency 
Control 
1735.8 
731.3 
2843 
81.25 18.75 
1735.8 
4984.1 
81.25 6.25 
1735.8 
731.3 
68.75 6.25 
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Moreover, the ms/ms data were elaborated to extract M.W. intact peptide information 
with “in-house” developed cig-win algorithm, to create matrix for PCA analysis. The 
elaboration carry out .a consistence reduction of data set, displayable in a tri-dimensional 
scatter plot (fig.16) showing an effective separation in two clusters (healthy and inhealthy). 
Thus PCA give us a predictive tool to discriminate sample.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          (Fig 16) Tridimensional Scatter plot. 
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DISCUSSION 
 
 In conclusion, This study was focused on the development and application of 
metabolomics technologies to peptides in urine of Bladder Cancer.  
In order to isolate selectively small organic molecules fraction of a complex substrate, 
like urine, was necessary to develop a purification method, to produce the highest content of 
metabolites and minor amounts of interference, we had testing a wide variety of protocols and 
techniques.  
We have also tested more instrument setup to increase: number, repeatability and 
stability of information obtained by mass spectrometry. The was coupled SEC with DT to 
sample preparation and nanoLC-nanoESI-Q-TOF like analyzer. 
Mathematic elaboration of the molecular masses of the series of peptides obtained by 
pathologic and healthy urine to feature selection has given some particular or important 
abundant targets that are present in tumours and are relatively or scarsely present or absent in 
controls. The cluster formed by these series of peptides might provide an early, rapid and non 
invasive diagnosis system at a relatively low cost. 
The ms/ms data were elaborated to extract M.W. intact peptide information with “in-
house” developed cig-win algorithm, to create matrix for PCA analysis. The elaboration carry 
out .a consistence reduction of data set, displayable in a tri-dimensional scatter plot showing 
an effective separation in two clusters (healthy and inhealthy). Thus PCA give us a predictive 
tool to discriminate sample. 
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